PMID- 10023509
OWN - NLM
STAT- MEDLINE
DCOM- 19990507
LR  - 20190815
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 45
IP  - 3
DP  - 1999 Feb 1
TI  - Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no 
      evidence for an altered benzodiazepine receptor sensitivity in panic disorder.
PG  - 321-6
AB  - BACKGROUND: Flumazenil is a benzodiazepine receptor antagonist thought to be 
      panicogenic in patients with panic disorder but not in control subjects. The 
      present study was undertaken to compare the effects of flumazenil in patients 
      with panic disorder and those in healthy control subjects, and also to determine 
      whether panic disorder is characterized by a hypothesized shift in the 
      benzodiazepine receptor "set-point" and a differential response to flumazenil. 
      METHODS: Eight patients with panic disorder and 8 matched control subjects were 
      given infusions of saline and flumazenil in randomized order. Psychopathological 
      changes, cardiovascular parameters, together with adrenocorticotropic hormone 
      (ACTH) and cortisol secretion were recorded. RESULTS: Patient and control 
      subjects responded to flumazenil uniformly; there was no evidence for an 
      anxiogenic activity of flumazenil in control subjects or panic disorder patients. 
      ACTH and cortisol levels were also not differentially influenced by flumazenil or 
      panic disorder diagnosis. Heart rate and systolic blood pressure in both groups 
      were slightly but significantly reduced by flumazenil compared to saline. 
      CONCLUSIONS: These findings do not support the view that panic disorder patients 
      and control subjects respond differentially to flumazenil or that the suggested 
      shift in the benzodiazepine receptor "set-point," which leads to an inverse 
      agonistic activity of flumazenil, characterizes panic disorder.
FAU - Strohle, A
AU  - Strohle A
AD  - Max Planck Institute of Psychiatry, Munich, Germany.
FAU - Kellner, M
AU  - Kellner M
FAU - Holsboer, F
AU  - Holsboer F
FAU - Wiedemann, K
AU  - Wiedemann K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (GABA Modulators)
RN  - 0 (Receptors, GABA-A)
RN  - 40P7XK9392 (Flumazenil)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
CIN - Biol Psychiatry. 1999 Dec 15;46(12):1709-11. PMID: 10624555
MH  - Adrenocorticotropic Hormone/blood/drug effects
MH  - Adult
MH  - Affective Symptoms/*chemically induced
MH  - Analysis of Variance
MH  - Arousal/drug effects
MH  - Behavioral Symptoms/chemically induced
MH  - Blood Pressure/drug effects
MH  - Case-Control Studies
MH  - Double-Blind Method
MH  - Female
MH  - Flumazenil/adverse effects/*pharmacology
MH  - GABA Modulators/adverse effects/*pharmacology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Male
MH  - Panic Disorder/blood/*physiopathology
MH  - Receptors, GABA-A/*drug effects/physiology
MH  - Time Factors
EDAT- 1999/02/19 04:30
MHDA- 2000/05/08 09:00
CRDT- 1999/02/19 04:30
PHST- 1999/02/19 04:30 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 1999/02/19 04:30 [entrez]
AID - S0006-3223(98)00295-9 [pii]
AID - 10.1016/s0006-3223(98)00295-9 [doi]
PST - ppublish
SO  - Biol Psychiatry. 1999 Feb 1;45(3):321-6. doi: 10.1016/s0006-3223(98)00295-9.